EA201591977A1 - Противораковая терапия анти-egfr антителами, имеющими низкое фукозилирование - Google Patents

Противораковая терапия анти-egfr антителами, имеющими низкое фукозилирование

Info

Publication number
EA201591977A1
EA201591977A1 EA201591977A EA201591977A EA201591977A1 EA 201591977 A1 EA201591977 A1 EA 201591977A1 EA 201591977 A EA201591977 A EA 201591977A EA 201591977 A EA201591977 A EA 201591977A EA 201591977 A1 EA201591977 A1 EA 201591977A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
antibodies
foocosyling
low
egfr
Prior art date
Application number
EA201591977A
Other languages
English (en)
Russian (ru)
Inventor
Штеффен Голетц
Антье Даниельчик
Original Assignee
Гликотоп Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гликотоп Гмбх filed Critical Гликотоп Гмбх
Publication of EA201591977A1 publication Critical patent/EA201591977A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201591977A 2013-04-22 2014-04-22 Противораковая терапия анти-egfr антителами, имеющими низкое фукозилирование EA201591977A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13002108 2013-04-22
EP13002106 2013-04-22
PCT/EP2014/058118 WO2014173886A1 (en) 2013-04-22 2014-04-22 Anti-cancer treatments with anti-egfr antibodies having a low fucosylation

Publications (1)

Publication Number Publication Date
EA201591977A1 true EA201591977A1 (ru) 2016-06-30

Family

ID=50729450

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591977A EA201591977A1 (ru) 2013-04-22 2014-04-22 Противораковая терапия анти-egfr антителами, имеющими низкое фукозилирование

Country Status (13)

Country Link
US (1) US20160068609A1 (https=)
EP (1) EP2989126A1 (https=)
JP (1) JP2016516800A (https=)
KR (1) KR20150144804A (https=)
CN (1) CN105229030A (https=)
AU (1) AU2014257650A1 (https=)
BR (1) BR112015025955A2 (https=)
CA (1) CA2908819A1 (https=)
EA (1) EA201591977A1 (https=)
MX (1) MX2015014773A (https=)
SG (1) SG11201507743XA (https=)
WO (1) WO2014173886A1 (https=)
ZA (1) ZA201507246B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
CN105820248A (zh) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型抗egfr单克隆抗体的制备方法及应用
CN105399830B (zh) * 2015-09-08 2019-11-19 北京天广实生物技术股份有限公司 抗egfr人源化单克隆抗体、其制备方法及用途
US20170247458A1 (en) * 2016-01-10 2017-08-31 Sorrento Therapeutics, Inc. Safety for Treating Cancers with a Glycosylated Chimeric Antibody to EGFR
ES2912903T3 (es) * 2016-04-27 2022-05-30 Green Cross Corp Composición farmacéutica para inhibir la metástasis del cáncer, que comprende, como principio activo, un anticuerpo que se une específicamente al receptor del factor de crecimiento epidérmico
CN116333130A (zh) * 2016-05-24 2023-06-27 英斯梅德股份有限公司 抗体及其制备方法
EP3484520A4 (en) 2016-07-13 2020-07-29 Reform Biologics, LLC STABILIZING EXCIPIENTS FOR THERAPEUTIC PROTEIN FORMULATIONS
KR101884614B1 (ko) 2016-10-11 2018-08-02 신일제약주식회사 Fab 단편 및 이의 용도
US20200148785A1 (en) * 2017-03-29 2020-05-14 Glycotope (GmbH) Pd-l1 and ta-muc1 antibodies
KR102702926B1 (ko) * 2017-04-13 2024-09-06 사이로파 비.브이. 항-sirp 알파 항체
CN111108123A (zh) * 2017-05-29 2020-05-05 加马玛布斯制药公司 癌症相关的免疫抑制抑制剂
WO2019222282A1 (en) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
JP7493237B2 (ja) * 2018-11-14 2024-05-31 学校法人金沢医科大学 びまん性胃がんを治療するための医薬組成物
CN112300278A (zh) * 2019-07-25 2021-02-02 上海交通大学 抗人egfr嵌合抗体及其制备方法和用途
TW202206460A (zh) * 2020-04-24 2022-02-16 荷蘭商美勒斯公司 使用結合lgr5及egfr之抗體的癌症治療
CN115960214A (zh) * 2021-10-12 2023-04-14 中国科学院分子细胞科学卓越创新中心 中和呼吸道合胞病毒的全人抗体的设计及应用
EP4476263A4 (en) * 2022-02-09 2026-01-28 Dragonfly Therapeutics Inc PHARMACEUTICAL FORMULATIONS AND THERAPEUTIC USES OF MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO EGFR, NKG2D AND CD16

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
PL1871805T3 (pl) * 2005-02-07 2020-03-31 Roche Glycart Ag Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania
EP3539981A1 (en) 2006-09-10 2019-09-18 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
WO2011101328A2 (en) * 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
PT2603528T (pt) * 2010-08-10 2016-12-01 Glycotope Gmbh Anticorpos glicosilados em fab
EP2603527A1 (en) * 2010-08-10 2013-06-19 Glycotope GmbH Humanized egfr antibodies

Also Published As

Publication number Publication date
CA2908819A1 (en) 2014-10-30
US20160068609A1 (en) 2016-03-10
SG11201507743XA (en) 2015-11-27
KR20150144804A (ko) 2015-12-28
BR112015025955A2 (pt) 2017-10-17
AU2014257650A1 (en) 2015-11-12
CN105229030A (zh) 2016-01-06
JP2016516800A (ja) 2016-06-09
EP2989126A1 (en) 2016-03-02
MX2015014773A (es) 2016-03-04
ZA201507246B (en) 2016-12-21
WO2014173886A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
EA201591977A1 (ru) Противораковая терапия анти-egfr антителами, имеющими низкое фукозилирование
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
PT2958945T (pt) Terapia de combinação envolvendo anticorpos contra claudina 18.2 para tratamento de cancro
EA201790932A1 (ru) Дозировка и введение нефукозилированных анти-cd40 антител
EA201790180A1 (ru) Способы и терапевтические комбинации для лечения опухолей
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA201590987A1 (ru) Соединения и способы их применения
EA201590997A1 (ru) Соединения и способы их применения
HK1221424A1 (zh) 治疗癌症的药物组合
GEP20217317B (en) Combination therapy for the treatment of cancer
MX384751B (es) Tratamiento del cáncer con una combinación de plinabulina y taxano.
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX2016007445A (es) Inhibidores de f1f0-atpasa de trifluorometil pirazolil guanidina y usos terapeuticos de los mismos.
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
ZA201708686B (en) Nanoparticles for use as a therapeutic vaccine
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
EA201791814A1 (ru) Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
NZ701974A (en) Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation
EA201791819A1 (ru) Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина
EA201690445A1 (ru) Лечение рака